AIGH Capital Management LLC Decreases Holdings in Biodesix, Inc. (NASDAQ:BDSX)

AIGH Capital Management LLC lowered its position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 30.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,272,591 shares of the company's stock after selling 1,907,221 shares during the quarter. Biodesix accounts for approximately 1.1% of AIGH Capital Management LLC's investment portfolio, making the stock its 25th largest position. AIGH Capital Management LLC owned approximately 2.92% of Biodesix worth $2,671,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Balyasny Asset Management L.P. acquired a new position in shares of Biodesix in the fourth quarter valued at approximately $29,000. HighTower Advisors LLC increased its stake in shares of Biodesix by 17.1% in the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company's stock valued at $236,000 after buying an additional 22,500 shares during the period. Geode Capital Management LLC increased its stake in shares of Biodesix by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 827,199 shares of the company's stock valued at $1,266,000 after buying an additional 22,623 shares during the period. Millennium Management LLC increased its stake in shares of Biodesix by 20.2% in the fourth quarter. Millennium Management LLC now owns 198,671 shares of the company's stock valued at $304,000 after buying an additional 33,329 shares during the period. Finally, Boothbay Fund Management LLC acquired a new position in shares of Biodesix in the fourth quarter valued at approximately $52,000. Institutional investors and hedge funds own 20.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on BDSX shares. Lake Street Capital lowered their price objective on Biodesix from $3.00 to $2.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. William Blair reiterated a "market perform" rating on shares of Biodesix in a report on Wednesday, May 14th. Canaccord Genuity Group reduced their target price on Biodesix from $2.50 to $1.50 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Craig Hallum reduced their target price on Biodesix from $3.00 to $1.50 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Scotiabank reduced their target price on Biodesix from $3.00 to $2.00 and set a "sector outperform" rating on the stock in a report on Wednesday, May 21st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1.75.

Biodesix Trading Up 18.0%

Shares of Biodesix stock traded up $0.06 on Wednesday, reaching $0.42. 3,372,365 shares of the company's stock were exchanged, compared to its average volume of 2,512,248. The company has a market capitalization of $62.26 million, a P/E ratio of -1.46 and a beta of 0.97. Biodesix, Inc. has a 52 week low of $0.17 and a 52 week high of $2.04. The firm's 50-day moving average is $0.30 and its two-hundred day moving average is $0.64. The company has a debt-to-equity ratio of 3.32, a quick ratio of 2.22 and a current ratio of 2.22.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). Biodesix had a negative return on equity of 167.28% and a negative net margin of 54.28%. The company had revenue of $17.96 million for the quarter, compared to analyst estimates of $19.50 million. Sell-side analysts predict that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.